GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The obesity epidemic is attributable to dietary and behavioral trends acting on a person's
genetic makeup to determine body mass and susceptibility to obesity-related diseases.
Furthermore, common forms of obesity have a strong hereditary component and many genetic
pathways that contribute to obesity have already ben identified.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that potentiates glucose-stimulated
insulin secretion. However, GLP-1 also acts as an appetite-inhibiting hormone affecting the
appetite center in the hypothalamus. Today, GLP-1 receptor agonists are available for the
treatment of type 2 diabetes, and their treatment potential in obesity is an area of active
research.
The aim of this study is to explore if the appetite inhibiting effect of GLP-1 is intact in
people diagnosed with obesity causing genetic disorders and to investigate the physiological
role of GLP-1 on food intake and appetite regulation in this group.